StockNews.AI
FDMT
StockNews.AI
130 days

4DMT Announces New Employment Inducement Grants

1. 4DMT granted 16,500 RSUs to attract new non-executive employees. 2. The Employment Inducement Award Plan aims to enhance recruitment efforts. 3. 4D-150 targets retinal diseases, currently in Phase 3 trials. 4. 4D-710 shows promise for cystic fibrosis with aerosol delivery of CFTR. 5. Product candidates are still in clinical or preclinical stages.

4m saved
Insight
Article

FAQ

Why Bullish?

The RSU grant indicates a focus on talent acquisition, which strengthens operational capabilities. Historically, companies that attract skilled employees see enhanced performance and stock growth.

How important is it?

The article highlights key operational strategies and product development that directly affects FDMT’s market position.

Why Short Term?

Immediate hiring initiatives can lead to operational improvements and upcoming trial advancements. Talent acquisition can foster growth and innovation in product development.

Related Companies

VRTXREGNCEGETSRX
EMERYVILLE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on April 8, 2025, the compensation committee of the Company’s board of directors granted three new non-executive employees 16,500 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company. About 4DMT 4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Our lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Our lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. Our second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT. All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied. Learn more at www.4DMT.com and follow us on LinkedIn. Contacts: Media: Jenn Gordondna CommunicationsMedia@4DMT.com Investors: Julian PeiHead of Investor Relations and Corporate FinanceInvestor.Relations@4DMT.com

Related News